Business Context and Reporting Period
Creative Medical Technology Holdings, Inc. filed this Form 8-K on December 22, 2020, reporting events occurring between December 22 and December 31, 2020. The Company is a Nevada corporation focused on the development of its ImmCelz® product.
Key Financial Metrics
This filing does not provide specific financial data. There are no reported values for revenue, profit, cash flow, margins, debt, or liquidity in this document.
Material Changes
The filing details three significant scientific and intellectual property developments regarding the ImmCelz® product:
- December 22, 2020: Identification of a primary mechanism of action for ImmCelz® in the treatment of stroke.
- December 29, 2020: Reporting of data and a related patent filing regarding ImmCelz®'s ability to reverse liver failure in a carbon tetrachloride preclinical model of hepatocyte necrosis.
- December 31, 2020: Reporting of a patent filing based on positive preclinical data for ImmCelz® in the treatment of a heart attack model.
Guidance, Outlook, and Risks
The filing contains no forward-looking financial guidance, management commentary on future performance, or specific risk factors beyond the inherent nature of preclinical research. The Company highlighted positive preclinical data and patent filings as key milestones.
Investor Verification Checklist
- Verify the content of the three press releases attached as Exhibits 99.1, 99.2, and 99.3.
- Confirm the status of the patent filings mentioned for liver failure and heart attack treatments.
- Review subsequent filings for updates on the clinical progression of ImmCelz® for stroke, liver failure, and heart attack.
- Check the Company's most recent 10-K or 10-Q for current financial health, as this 8-K contains no financial statements.